Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Please visit answersincme.com/860/240201301-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss how the latest evidence on frontline immunotherapy-based regimens can be integrated into practice to optimize outcomes for patients with advanced NSCLC. Upon completion of this activity, participants should be better able to: Review the latest data on frontline immunotherapy-based regimens for the treatment of advanced NSCLC; Identify patient-, disease-, and drug-related factors that may inform the frontline use of immunotherapy-based regimens for advanced NSCLC; and Outline evidence-based, multidisciplinary strategies to optimize long-term patient outcomes with frontline immunotherapy-based regimens in advanced NSCLC.

There are no comments yet.

Please log in to write the first comment.